A pioneering cancer detection system utilizing artificial intelligence (AI) technology is set to be unveiled by British GP Dr Bea Bakshi at the American Society of Clinical Oncology (ASCO) conference in Chicago. Dr Bakshi, the co-founder and CEO of the UK-based cancer detection system C the Signs, will present groundbreaking findings from a study showcasing the system’s ability to transform early cancer diagnosis and improve survival rates.

The study, which involved 118,677 patients, demonstrated the highly sensitive nature of the C the Signs system in real-life scenarios. It effectively detected cancer, ensuring that patients at risk of the disease were not missed during risk assessment. Additionally, the system exhibited accuracy in identifying the origin of cancer, enabling doctors to triage patients appropriately for treatment.

Dr Bakshi expressed great enthusiasm about the study’s results, stating, “The accuracy of using AI technology in a real-world setting is extremely exciting. With more usage, the system will become even more sensitive, accurate, and effective. We have additional unpublished data that shows even better outcomes as the system evolves, and we will be disclosing the specifics soon.”

C the Signs assessed 118,677 patients, with 7,295 subsequently diagnosed with cancer. The system correctly identified 7,056 patients as being at risk of cancer, demonstrating a sensitivity of 96.7%. Moreover, C the Signs exhibited a negative predictive value of 97.2%, accurately ruling in and ruling out cancer cases. In 85.6% of patients diagnosed with cancer, the system correctly identified the origin of the disease.

Over 1,000 primary care practices and 15,000 healthcare professionals in the UK are already utilizing the C the Signs platform. Dr Bakshi and her team have now expanded their reach to the United States and are forging partnerships with US health systems.

The presentation of the study coincides with the launch of the CancerX initiative as part of the Cancer Moonshot program, spearheaded by the White House and President Biden. Dr Bakshi believes that C the Signs technology will play a significant role in achieving CancerX’s ambitious goal of reducing cancer mortality by 50% by 2040.

As a founding member of CancerX, C the Signs joins forces with other organizations committed to advancing cancer research and treatment through digital innovation. The collaboration aims to establish best practices, build capacity, and demonstrate the impact of innovation on every individual’s cancer journey.

The groundbreaking AI technology showcased by C the Signs has the potential to revolutionize cancer prediction and detection, contributing to the overarching goal of reducing cancer mortality rates.

Dr Bakshi will present the results of the C the Signs study at the McCormick Place Convention Center in Chicago today (Monday 5th June). More details about the study can be found here: https://meetings.asco.org/abstracts-presentations/219520.